Drug Database
LA

lamotrigine orally disintegrating tablet (lamotrigine ODT / lamictal ODT / EUR1048)

✓ Approved

Adare Pharma Solutions · SCN1A · 小分子

什么是 lamotrigine orally disintegrating tablet?

lamotrigine orally disintegrating tablet 是一种小分子,由Adare Pharma Solutions研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名lamotrigine ODT, lamictal ODT, EUR1048
公司Adare Pharma Solutions
药物类别小分子
分子靶点SCN1A, SCN2A, SCN3A
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

lamotrigine orally disintegrating tablet 作用于 3 个分子靶点:

SCN1Asodium voltage-gated channel alpha subunit 1 (DEE6B, FEB3)
SCN2Asodium voltage-gated channel alpha subunit 2 (Na(v)1.2, BFNIS)
SCN3Asodium voltage-gated channel alpha subunit 3 (Nav1.3, NAC3)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

lamotrigine orally disintegrating tablet 针对 4 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Nervous system disordersGeneralised tonic-clonic seizure✓ Approved
Nervous system disordersLennox-Gastaut syndrome✓ Approved
Psychiatric disordersBipolar disorder✓ Approved
Nervous system disordersPartial seizures✓ Approved

相关研究文献

PubMedParasites & vectors2026-11-19

Probiotic potential of Blautia producta L1 in mitigating Eimeria tenella-induced intestinal inflammation and dysbiosis in chickens.

Liu Jianhua J, Yuan Cheng C, Zhang Guangji G, Zhao Changjing C et al.

The capacity of Blautia to restore microbial homeostasis and attenuate intestinal inflammation highlights its potential as a promising microbial therapeutic for poultry coccidiosis. A total of 75 one-day-old male Hy-Line layer chicks were randomly allocated into five groups (n=15 per group): mock control, challenged control, B. producta L1 control, B. producta L1-challenged, and inactivated B. producta L1-challenged. From day 1 to day 22, chickens in the B. producta L1-treatment groups were orally administered either live or heat-inactivated B. producta L1 at 2 × 10⁸ CFU/mL (1 mL/bird) once daily. On day 14, chickens in the challenged groups were orally gavaged with 3 × 104 sporulated E. tenella oocysts. Protective efficacy was assessed by body weight gain, fecal oocyst out, cecal lesion score (0-4), and histopathological examination of intestinal epithelium. The anticoccidial index (ACI) was also calculated. Inflammatory cytokines including IL-1β, IL-6, TNF-α, and IL-10 were analyzed by ELISA, and mRNA expression of genes related to cecal inflammatory pathways was analyzed by qRT-PCR. The composition of the cecal microbiota was profiled using 16S rRNA gene sequencing. Supplementation with either live or heat-inactivated B. producta L1 conferred measurable protection against E. tenella challenge. Body weight gain in the live and inactivated B. producta L1-treated groups was significantly greater than that of the challenged control group (p < 0.01). Cecal lesion scores and fecal oocyst output were markedly reduced in both B. producta L1-treated groups compared with the challenged control group (p < 0.001 for both). Survival was 100% in both B. producta L1-treated groups and 86.7% (13/15) in the challenged control group. However, the between-group difference in survival was not statistically significant. The ACI values of the live and inactivated B. producta L1-treated groups were 162.0 and 151.6, respectively, corresponding to medium-effective and effective protection according to the established ACI criteria, compared with 102.2 in the challenged control group. Histopathological examination showed less epithelial degeneration, necrosis, and villus atrophy in B. producta L1-treated birds. Moreover, B. producta L1 supplementation significantly decreased serum concentrations of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α; p < 0.01) and increased the anti-inflammatory cytokine IL-10 (p < 0.05), while downregulating mRNA expression of TLR4, MYD88, NF-κB, NLRP3, P65, and Caspase-3 in cecal tissues (p < 0.05 for all). 16S rRNA gene sequencing further demonstrated that B. producta L1 increased cecal microbial richness and diversity, with higher relative abundances of beneficial genera such as Blautia and Lactobacillus and lower abundances of potentially pathogenic taxa including Salmonella, Acinetobacter, and Erysipelatoclostridium (p < 0.05). B. producta L1 moderately ameliorates E. tenella-induced pathology by helping preserve intestinal barrier integrity, dampening inflammatory responses, and reshaping the gut microbial ecosystem. These findings support B. producta L1 as a promising probiotic or postbiotic candidate for complementary control of E. tenella infection in poultry, although further benchmarking against standard anticoccidial agents and identification of active bioactive components are required.

PMID 43053077
阅读全文 →
PubMedVeterinary medicine and science2026-11-19

Cutaneous Effects of Oral Polystyrene Microplastic Exposure in Mice: Oxidative Stress, Inflammation, and FGF5 Gene Dysregulation.

Islam Md Sadequl MS, Koedrith Preeyaporn P

Microplastic (MP) pollution represents an escalating threat to mammalian health, yet the potential effects of oral MP exposure on mammalian skin remain poorly understood. This study investigated the effects of oral polystyrene microplastic (PS-MP) exposure on skin integrity, oxidative balance, and the expression of the Fibroblast Growth Factor 5 (FGF5) gene a key regulator controlling the transition between hair growth and regression phases in the hair cycle. Male Swiss albino mice were orally exposed to PS-MPs (4.8-5 µm) at low (0.1 mg) and high (0.2 mg) doses for 28 consecutive days. Biochemical analyses evaluated oxidative stress markers (CAT, SOD, POD, ROS, and MDA), serum enzyme activity (ALT, AST, ALP, and amylase), and mineral concentrations (Ca, Mg, and phosphate). Histopathological examination of H&E-stained skin sections assessed epidermal thickness, keratinocyte density, and dermal inflammation. Quantitative real-time PCR was used to measure FGF5 gene expression in dorsal skin, with Hprt1 as the internal control. Oral PS-MP exposure was associated with dose-dependent oxidative stress in skin tissue, reflected by elevated ROS (0.545 → 1.99 U/mg) and MDA (1.49 → 7.37 nmol/L) levels and significant depletion of antioxidant enzymes such as CAT (10.2 → 4.33 U/mg protein). Serum biochemical disturbances confirmed systemic metabolic stress. Histopathology revealed epidermal hyperplasia (16.46 → 34.18 µm), reduced keratinocyte density (22.1 → 7.0), and marked inflammatory infiltration. Importantly, FGF5 expression increased 1.35-fold, suggesting altered regulation of pathways associated with hair-follicle cycling. Oral PS-MP exposure was associated with oxidative stress, structural alterations, inflammation, and FGF5 upregulation in mouse skin. These findings suggest a potential association between oral PS-MP exposure and disruption of skin and hair-follicle homeostasis in mammals.

PMID 43052231
阅读全文 →
PubMedCureus2026-11-18

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome in an Adolescent Girl With Epilepsy: A Case Report of Severe Multorgan Involvement.

Cherrat Achraf A

Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a rare but potentially life-threatening severe cutaneous adverse drug reaction characterized by a delayed onset of fever, extensive skin eruption, hematologic abnormalities, and internal organ involvement. Antiepileptic drugs are among the most frequently implicated medications. Early recognition and prompt withdrawal of the culprit drug with appropriate treatment are essential to prevent severe complications such as multiorgan failure. We report the case of a 15-year-old girl with autism spectrum disorder treated for uncontrolled epilepsy requiring multiple antiepileptic medications who developed severe DRESS syndrome seven to eight weeks after initiation of lamotrigine. The patient presented with mucocutaneous lesions with fever, eosinophilia, acute kidney injury, severe hepatocellular damage, respiratory manifestations, and a marked inflammatory response. DRESS was diagnosed using the RegiSCAR criteria. Carbamazepine and lamotrigine were immediately discontinued and replaced with levetiracetam. Systemic corticosteroid therapy at 1 mg/kg/day was initiated with supportive management. Despite an initial improvement, the patient's clinical condition deteriorated again, followed by fatal respiratory failure. This case highlights the diagnostic complexity and potentially fulminant course of pediatric DRESS, particularly when multiple systemic organs are involved, and urges clinicians to maintain a high index of suspicion for DRESS in children receiving aromatic antiepileptic drugs who develop fever and a generalized rash several weeks after treatment initiation.

PMID 43048144
阅读全文 →
PubMedAnalytical chemistry2026-11-18

MALDI-TOF Mass Spectrometry Imaging for Spatially Resolved Degradation Profiling of Solid Formulations.

Thomas Rekha R, Vargas Karina A KA, Shi Zhenqi Z, Gruenhagen Jason J et al.

Understanding the stability of the active pharmaceutical ingredient (API) and drug-excipient interactions is critical for ensuring the efficacy and shelf life of pharmaceutical formulations. This study applies matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) to investigate two-dimensional (2D) and three-dimensional (3D) spatial profiling of degradants in Losartan potassium tablets that are subjected to temperature- and humidity-induced stress conditions. This approach allows for in situ visualization of API degradation and excipient compatibility within solid dosage forms. Upon stress, Losartan tablets formed dimeric and trimeric species as major degradation products. Spatial mapping revealed a gradual growth of these degradants from the control (T0) through four weeks of stress. Ion images showed distinct heterogeneity in the formation of dimer and trimer species across the tablet depth and plane; however, no preferential pattern was observed at the tablet periphery. The random distribution of degradants suggests that alongside humidity, localized microenvironments drive the degradation process. MALDI-MSI demonstrates strong potential as a high-throughput and sensitive alternative to traditional liquid chromatography-based procedures for early-stage formulation screening. Furthermore, this work suggests that when integrated with orthogonal techniques to coregister excipient domains, MALDI-MSI can serve as an emerging tool to uniquely characterize drug-excipient interactions during early-stage drug development. This provides spatially resolved insight that enhances accelerated stability assessment programs and streamline the selection of compatible excipients.

PMID 43046425
阅读全文 →
PubMedClinical case reports2026-11-18

Supervised Combined Exercise as an Intervention in Treatment-Resistant Depression: A Mixed-Methods Case Report.

Etxaniz-Oses José J, Tous-Espelosin Mikel M, Orruño-Vivar Julene J, Maldonado-Martin Sara S et al.

Treatment-resistant depression (TRD) remains a severe clinical condition associated with persistent symptomatology, functional impairment, and unhealthy lifestyle patterns. This case report examines the effects of a supervised combined exercise intervention using a mixed-methods approach. A 55-year-old woman with a 13-year history of TRD treated with clomipramine (150 mg/day), lamotrigine (400 mg/day), and bromazepam (3 mg/day) presented with moderate depressive symptoms (Montgomery-Åsberg Depression Rating Scale [MADRS] = 28; Clinical Global Impressions Scale [CGI-S] = 4), marked sedentary behavior (approximately 13 h/day), low cardiorespiratory fitness (CRF) (VO2peak = 18 mL·kg-1·min-1), and elevated fat mass (42%). She participated in a 12-week supervised combined exercise programme (aerobic and resistance training, twice weekly) within the TRACE-RMD framework. Following the intervention, depressive symptoms decreased by 57% (MADRS = 12), with remission of global illness severity (CGI-S = 1) and a 16.7% increase in CRF. Functional disability and perceived stress were substantially reduced, while perceived social support markedly increased, as assessed by the Sheehan Disability Inventory (the global score reflects disability, item 4 reflects perceived stress, and item 5 reflects social support). Qualitative narratives indicated improvements in mood regulation, reduced rumination, increased self-efficacy, and enhanced social reintegration. Supervised combined exercise may represent a feasible and clinically meaningful adjunctive intervention in TRD, acting not only on symptom reduction but also on functional recovery and psychosocial re-engagement. Further controlled studies are warranted. The study was registered at ClinicalTrials.gov identifier (NCT05136027).

PMID 43047576
阅读全文 →
PubMedTherapeutic advances in neurological disorders2026-11-18

Non-ischemic cerebral enhancing (NICE) lesions after extracranial carotid stenting: A case report.

von Itter Jonas J, von Itter Marc-Nicolas MN, Härtel Lucia L, Pawlowski Matthias M et al.

Non-ischemic cerebral enhancing (NICE) lesions are exceptionally rare complications of neuroendovascular procedures and have been reported predominantly after intracranial interventions, with only one previous case following extracranial carotid stenting. We report a second such case. A woman in her mid-thirties with inactive Takayasu arteritis underwent long-segment extracranial stenting of asymptomatic stenoses of the left common (CCA) and internal carotid (ICA) arteries using three overlapping stents. Eighteen days after the procedure, she developed new-onset headache; MRI showed a small left parieto-occipital hemorrhage and multiple ipsilateral NICE lesions. Serial MRI over 10 months demonstrated asynchronous NICE lesion behavior, with simultaneous emergence, regression, and persistence of ipsilateral and contralateral foci. Their non-ischemic morphology and the absence of clinical, laboratory, CSF, or vascular imaging evidence of active vasculitis argued against a Takayasu-related origin. Despite fluctuating lesion burden, she developed no persistent neurological deficits and required no long-term immunosuppressive therapy. Mild headaches and a one-day cluster of focal sensory seizures occurred, with no recurrence under low-dose lamotrigine. This case provides further evidence that NICE lesions are not confined to intracranial procedures and may also follow extracranial carotid stenting, showing highly variable lesion dynamics. The continued appearance of new lesions up to 308 days after stenting suggests persistent microembolization or delayed inflammatory manifestation of initially occult embolic deposits rather than a purely one-time periprocedural event. The divergence between radiological lesion burden and clinical severity further suggests that management should be guided primarily by the clinical course and that conservative management may be appropriate in clinically stable patients.

PMID 43048245
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多lamotrigine orally disintegrating tablet